Insulin secretion: difference between revisions
Diff·revision 16 → 17·13:45, 19 May 2025
Difference between revision 16 and revision 17 of Insulin secretion. 3 lines changed; the page grew by 404 bytes.
| Revision 16 — 12:29, 25 Apr 2025 SerialCommaSeb (talk) British spelling per PP:MOS 5,969 bytes +527 | Revision 17 — 13:45, 19 May 2025 TesamorelinTeg (talk) add the citation for the co-secretion finding 6,373 bytes +404 | ||
|---|---|---|---|
| 36 | Anyone comparing published secretion data should check which measure was used. Fasting insulin, HOMA-B, C-peptide deconvolution and clamp-derived first-phase measurements are not interchangeable, and a difference between studies is as likely to be methodological as physiological.{{r|bergman2002}} | 36 | Anyone comparing published secretion data should check which measure was used. Fasting insulin, HOMA-B, C-peptide deconvolution and clamp-derived first-phase measurements are not interchangeable, and a difference between studies is as likely to be methodological as physiological.{{r|bergman2002}} |
| 37 | 37 | ||
| + | 38 | == Failure in type 2 diabetes == | |
| + | 39 | Beta-cell secretory failure, not insulin resistance alone, is what converts impaired glucose tolerance into diabetes. Cross-sectional data indicate a substantial loss of functional beta-cell capacity by the time of diagnosis, though estimates vary widely with the method used and post-mortem mass measurements do not track functional estimates closely.{{r|rorsman2013}} | |
| + | 40 | ||
| 38 | == References == | 41 | == References == |
| 39 | {{reflist}} | 42 | {{reflist}} |